Should You Buy, Sell or Hold Hikma Pharmaceuticals Plc And London Stock Exchange Group Plc After Today’s News?

Roland Head assesses the latest news from Hikma Pharmaceuticals Plc (LON:HIK) and London Stock Exchange Group Plc (LON:LSE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 250 pharmaceutical group Hikma Pharmaceuticals (LSE: HIK) dropped 5% in early trade this morning after the group said that a sharp fall in sales of a generic gout treatment had dented profits.

Diluted earnings

However, the market seems to have warmed to Hikma’s results as the day has progressed. At the time of writing, the shares are modestly higher. So was it good news or bad for this highly-rated stock?

Hikma’s total sales were down 3% while core operating profit was down 4%, to $409m. Post-tax profits were down by 9% to $252m, but the dividend was held unchanged at 32 cents for the full year.

This leaves Hikma stock trading on a trailing P/E of 18 and a trailing yield of 1.3%. On the face of it this is not especially cheap. However, the outlook for Hikma is dominated by the recent $2.1bn acquisition of Roxane, which is expected to add around $600m to revenue in 2016.

Market confidence in this deal was shaken in February when Hikma announced a $535m reduction in the price it would pay for Roxane. The revised deal was triggered by Hikma’s first sight of Roxane’s 2015 financial results. These showed that Roxane’s 2015 profits were likely to be slightly lower than in 2014.

Although Roxane is expected to add significantly to Hikma’s revenue in 2016, the firm now estimates that the acquisition “will be slightly dilutive to adjusted earnings per share in 2016”. What this means is that additional profits from Roxane will not be enough to offset the dilutive effect of the new shares which were issued in part-payment for Roxane.

This situation is expected to reverse in 2017, when Hikma expects earnings per share growth as a result of the Roxane deal. However, it does highlight the risk involved in major acquisitions. Hikma trades on a 2016 forecast P/E of about 18. This is probably reasonable, but I’d rather know more about Roxane’s contribution before deciding whether to buy.

A waiting game

The London Stock Exchange Group (LSE: LSE) published the long-awaited details of an all-share merger with Frankfurt stock exchange owner Deutsche Börse this morning.

The deal would give existing LSE shareholders a 45.6% share of the combined group, with existing Deutsche shareholders owning the remainder. Today’s statement claims that ongoing cost savings of €450m could be achieved, which would reduce the group’s combined operating costs of €2,200m by nearly 20%.

A second benefit would be that many big investors would also benefit from having to provide lower levels of collateral to the exchanges. This is because their open positions on the two exchanges would offset each other to some extent. This would reduce the level of margin payments that would be required.

However, the LSE-Deutsche Börse deal may not proceed. US Group Intercontinental Exchange (ICE) has already indicated its interest in making an offer. Analysts expect that such a deal might include a cash element, which could be more appealing to LSE shareholders.

Today’s deal seems sound enough to me, but an ICE offer could be more generous. If I was a London Stock Exchange shareholder, I would hold on and wait for further news.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should I buy National Grid shares for the big dividend before it’s too late?

This year's price weakness has left National Grid shares on what looks like a tempting valuation. I hope it doesn't…

Read more »